📊 ATYR Key Takeaways
Is aTYR PHARMA INC (ATYR) a Good Investment?
aTYR Pharma faces critical financial distress with revenue of only $190K against $12.5M annual operating cash burn, leaving less than one year of cash runway. The company exhibits the financial profile of an early-stage biotech with zero commercial traction, declining revenue (-19.1% YoY), and structurally unsustainable operations requiring immediate external funding or strategic pivot.
aTyr Pharma's fundamentals are very weak: revenue is negligible and declining, while operating and net losses remain massive relative to the size of the business. Although leverage is low and current liquidity ratios look strong, the combination of just $10.74M in cash against roughly $62.06M of annual free cash outflow points to significant funding risk and poor growth quality.
aTYR PHARMA INC Key Strengths (ATYR)
- Minimal debt burden with 0.05x debt-to-equity ratio
- Positive stockholders' equity of $57.9M provides balance sheet foundation
- Strong current ratio of 5.78x indicates technical liquidity despite operational distress
- Low balance-sheet leverage with debt/equity of 0.04x
- Current and quick ratios of 5.30x indicate limited near-term liability pressure
- Positive YoY EPS improvement suggests some cost discipline at the per-share level
ATYR Stock Risks: aTYR PHARMA INC Investment Risks
- Critical cash runway of approximately 10 months at current $12.5M annual burn rate with only $10M liquid reserves
- Negligible revenue of $190K against massive operating losses of $11.4M indicates zero commercial viability
- Declining year-over-year revenue trend (-19.1%) suggests deteriorating business momentum without offsetting cost reduction
- Revenue base is extremely small at $190K and declined 19.1% YoY
- Profitability is deeply negative with net loss of $74.12M and net margin around -39009.5%
- Cash burn is severe, with operating cash flow of -$61.99M versus only $10.74M of cash on hand
Key Metrics to Watch
- Cash position and runway - critical threshold for survival
- Operating cash burn rate - trend toward sustainability or accelerating deterioration
- Revenue inflection - any meaningful commercial progress or clinical milestone funding
- Quarterly operating cash burn relative to cash and equivalents
- Clinical/commercial revenue traction and any sustained reduction in operating loss
aTYR PHARMA INC (ATYR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.78x current ratio provides a solid financial cushion.
ATYR Profit Margin, ROE & Profitability Analysis
ATYR vs Healthcare Sector: How aTYR PHARMA INC Compares
How aTYR PHARMA INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is aTYR PHARMA INC Stock Overvalued? ATYR Valuation Analysis 2026
Based on fundamental analysis, aTYR PHARMA INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
aTYR PHARMA INC Balance Sheet: ATYR Debt, Cash & Liquidity
ATYR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: aTYR PHARMA INC's revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-0.94 indicates the company is currently unprofitable.
ATYR Revenue Growth, EPS Growth & YoY Performance
ATYR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$17.3M | $-0.23 |
| Q2 2025 | N/A | -$16.3M | $-0.22 |
| Q1 2025 | N/A | -$14.9M | $-0.17 |
| Q3 2024 | N/A | -$11.3M | $-0.20 |
| Q2 2024 | N/A | -$12.3M | $-0.22 |
| Q1 2024 | N/A | -$12.0M | $-0.23 |
| Q3 2023 | N/A | -$11.3M | $-0.20 |
| Q3 2021 | $148.0K | -$6.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
aTYR PHARMA INC Dividends, Buybacks & Capital Allocation
ATYR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for aTYR PHARMA INC (CIK: 0001339970)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATYR
What is the AI rating for ATYR?
aTYR PHARMA INC (ATYR) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATYR's key strengths?
Claude: Minimal debt burden with 0.05x debt-to-equity ratio. Positive stockholders' equity of $57.9M provides balance sheet foundation. ChatGPT: Low balance-sheet leverage with debt/equity of 0.04x. Current and quick ratios of 5.30x indicate limited near-term liability pressure.
What are the risks of investing in ATYR?
Claude: Critical cash runway of approximately 10 months at current $12.5M annual burn rate with only $10M liquid reserves. Negligible revenue of $190K against massive operating losses of $11.4M indicates zero commercial viability. ChatGPT: Revenue base is extremely small at $190K and declined 19.1% YoY. Profitability is deeply negative with net loss of $74.12M and net margin around -39009.5%.
What is ATYR's revenue and growth?
aTYR PHARMA INC reported revenue of $190.0K.
Does ATYR pay dividends?
aTYR PHARMA INC does not currently pay dividends.
Where can I find ATYR SEC filings?
Official SEC filings for aTYR PHARMA INC (CIK: 0001339970) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATYR's EPS?
aTYR PHARMA INC has a diluted EPS of $-0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ATYR's fundamental grade?
Based on our AI fundamental analysis in June 2026, aTYR PHARMA INC has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ATYR stock overvalued or undervalued?
Valuation metrics for ATYR: ROE of -18.6% (sector avg: 15%), net margin of -5,679.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ATYR's AI grade for 2026?
Our dual AI analysis gives aTYR PHARMA INC a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATYR's free cash flow?
aTYR PHARMA INC's operating cash flow is $-12.5M, with capital expenditures of $138.0K. FCF margin is -6,660.5%.
How does ATYR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,679.5% (avg: 12%), ROE -18.6% (avg: 15%), current ratio 5.78 (avg: 2).